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Background: Obesity-related metabolic disorders are closely associated with
inﬂammation induced by innate immunity. Toll-like receptors (TLRs) play a pivotal
role in the innate immune system by activating proinﬂammatory signaling path-
ways. GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an active immuno-
modulatory agent that primarily targets macrophages and inhibits secretion of
tumor necrosis factor α [as well as interleukin (IL)-1β, IL-10, and interferon g].
However, the effect of TLR antagonist on kidney diseases has rarely been reported.
We investigated whether the TLR antagonist GIT27 has beneﬁcial effects on the
progression of kidney disease in obese mice on a high-fat diet (HFD).
Methods: Six-week-old male C57BL/6 mice were divided into three groups: mice
fed with normal chow diet (N¼4); mice fed with a HFD (60% of total calories from
fat, 5.5% from soybean oil, and 54.5% from lard, N¼4); and GIT27-treated mice fed
with a HFD (N¼7).
Results: Glucose intolerance, oxidative stress, and lipid abnormalities in HFD mice
were improved by GIT27 treatment. In addition, GIT27 treatment decreased the
urinary excretion of albumin and protein in obesity-related kidney disease, urinary
oxidative stress markers, and inﬂammatory cytokine levels. This treatment inhibited
the expression of proinﬂammatory cytokines in the kidneys and adipose tissue, and
improved extracellular matrix expansion and tubulointerstitial ﬁbrosis in obesity-
related kidney disease.
Conclusion: TLR inhibition by administering GIT27 improved metabolic parameters.
GIT27 ameliorates abnormalities of lipid metabolism and may have renoprotective
effects on obesity-related kidney disease through its anti-inﬂammatory properties.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).n Society of Nephrology. Published by Elsevier. This is an open access article under the CC BY-NC-ND
c-nd/4.0/).
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Obesity, insulin resistance, type 2 diabetes, dyslipidemia,
and hypertension together comprise metabolic syndrome [1].
Obesity is also the most important risk factor for hypertension,
metabolic disease, diabetes mellitus, and chronic renal disease.
For a long time, the kidneys have been considered a victim of
metabolic syndrome, and abnormalities of lipid and glucose
metabolism in the kidneys are as important as those in adipose
tissue. Therefore, the possibility of cross-talk between adipose
tissue and the kidneys exists in metabolic syndrome, particu-
larly in chronic renal diseases related to insulin resistance such
as obesity and diabetes mellitus [2]. Injuries in the structures
of the kidney, leading to changes in renal structure including
glomerular hypertrophy, mesangial expansion, abnormalities
of the podocyte foot processes, increased glomerular capillary
wall tension, and vascular abnormalities, are observed in obese
humans and animals. These changes decrease the glomerular
ﬁltration rate and increase proteinuria or albuminuria [1,3,4].
Recent research suggests that obesity-related metabolic
disorders are closely associated with inﬂammation induced
by innate immunity. The adipose tissue contains adipocytes,
stromal-vascular cells, endothelial cells, ﬁbroblasts, and
macrophages. Obesity induces an increased inﬁltration of
activated macrophages into the adipose tissue. Macrophages
contribute to the increased secretion of proinﬂammatory
cytokines such as tumor necrosis factor α (TNFα), monocyte
chemoattractant protein-1 (MCP-1), interleukin (IL)-6, C-reac-
tive protein (CRP), and plasminogen activator inhibitor-1 (PAI-
1) in the adipose tissue. Obesity also induces an increase in
plasma free fatty acid (FFA) concentration due to the super-
saturation of fat storage in the adipose tissue. Increased levels
of proinﬂammatory cytokines and FFAs induce systemic
inﬂammation, oxidative stress, and insulin resistance through
the activation of immune receptors and stress signaling path-
ways [5–8].
Toll-like receptors (TLRs) belong to a family of pattern-
recognition receptors that play a pivotal role in the innate
immune system by activating proinﬂammatory signaling that
mainly helps in recognizing speciﬁc pathogen-associated mole-
cular patterns. These patterns include exogenous patterns such
as lipopolysaccharide (LPS), mycoplasma lipoproteins, viral and
bacterial nucleic acids, endogenous ligands such as heat shock
protein (HSP) 60 and HSP70, saturated fatty acids, unsaturated
fatty acids, hyaluronic acid fragment, and surfactant protein-A.
An increased plasma FFA level in obesity induces inﬂammation
through the TLR4 signaling pathway [9–12]. In previous studies,
TLR has been known to be associated with multiple renal
dysfunctions, including lupus nephritis, antibody-mediated glo-
merulonephritis, acute allograft rejection, endotoxin-induced
acute renal failure, kidney ischemia/reperfusion injury, and
diabetic kidney disease [13–18].
GIT27 (4,5-dihydro-3-phenyl-5-isoxasole acetic acid) is an
active immunomodulatory agent that primarily targets macro-
phages and inhibits the secretion of LPS-induced TNFα [as well
as IL-1β, IL-10, and interferon (IFN)-γ] via interference of the
macrophage TLR4 and TLR2/6 signaling pathways. In addition to
inhibiting proinﬂammatory cytokine synthesis, GIT27 inhibits
LPS-induced nuclear factor kappa B (NFκB) and p38 mitogen-
activated protein (MAP) kinase signaling pathways. GIT27 has
showed therapeutic effects in multiple inﬂammatory diseases,
including type 1 diabetes mellitus, rheumatoid arthritis, and
colitis [19–21]. In this study, we observed that animmunonodulator such as GIT27 has beneﬁcial effects on
obesity-related metabolic parameters, renal injury, and lipid
metabolism in both the kidneys and the adipose tissue.Methods
Animal experiments
C57BL/6 mice were caged individually under controlled
temperature (23721C) and humidity (5575%) with an artiﬁ-
cial light cycle. Six-week-old male C57BL/6 mice were divided
into three groups: mice fed with a normal chow diet (ND,
N¼4); mice fed with a high-fat chow diet (HFD, 60% of total
calories from fat, 5.5% from soybean oil, and 54.5% from lard;
N¼4); and GIT27-treated mice fed with a HFD (N¼7). GIT27
was purchased from Tocris Bioscience (Tocris Cookson, Ellis-
ville, MI, USA) and administered via an intraperitoneal route at
a dose of 20 mg/kg daily for 12 weeks. We measured the food
and water intake, urine volume, body weight, fasting blood
glucose concentration, and HbA1c level every month. Plasma
glucose level was measured using the glucose oxidase method,
and HbA1c level was calculated using the IN2IT system (Bio-
Rad Laboratories, Hercules, CA, USA). Plasma creatinine level
was determined using high-performance liquid chromatogra-
phy. Plasma insulin and adiponectin levels were measured
using an enzyme-linked immunosorbent assay (ELISA) kit
(Linco Research, St Charles, MO, USA). The homeostasis model
assessment index (HOMA-IR) was calculated using the follow-
ing formula: [fasting glucose (mmol/L) fasting insulin (mU/
L)/22.5]. Plasma triglyceride and cholesterol analyses were
performed using a GPO-Trinder kit (Sigma, St Louis, MO,
USA). For the glucose tolerance test, we performed oral gavage
of 3 g dextrose/kg in mice after a 5-hour fast and collected
blood samples through the tail vein. Individual mice were
separated in a metabolic cage where urine was collected and
measured for 24 hours every month to determine the amount
of urinary albumin excretion by competitive ELISA (Shibayagi,
Shibukawa, Japan), which was corrected by the urinary crea-
tinine concentration. The urinary level of 8-isoprostane was
measured using an ELISA kit (Cayman Chemical, Ann Arbor, MI,
USA). The levels of proinﬂammatory cytokines (IFN-γ and IL-2)
in urine were measured using the Millipore Milliplex mouse
cytokine/chemokine kit. At the end of the study period,
systolic blood pressure was measured using tail-cuff plethys-
mography (LE 5001-Pressure Meter; Letica SA, Barcelona,
Spain). Mice were sacriﬁced under anesthesia with intraper-
itoneal injections of sodium pentobarbital (50 mg/kg). Their
heart, epididymal fat, liver, and kidney tissues were extracted
and subsequently snap-frozen in liquid nitrogen. Lipids from
the hepatic, adipose, and renal cortical tissues were extracted
using the Bligh and Dyer method [22]. Total cholesterol and
triglyceride contents were measured using a commercial kit
(Wako Chemicals, Richmond, VA, USA). Plasma and tissue FFA
levels were also measured using a commercial kit (Abcam Plc,
Cambridge, MA, USA). The extent of peroxidative reaction in
the hepatic tissue, adipose tissue, and kidneys was determined
by direct measurement of lipid hydroperoxides (LPO) using an
LPO assay kit (Cayman Chemical), as described previously [23].
We performed all the experiments in accordance with the
guidelines of the National Institutes of Health and with the
approval of the Korea University Institutional Animal Care and
Use Committee.
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We ﬁxed kidney tissues in 4% paraformaldehyde and
embedded them in parafﬁn. They were then cut into 4-μm-thick
slices and stained with periodic acid–Schiff. Glomerular mesangial
expansion was scored semiquantitatively, and the percentage of
mesangial matrix occupying each glomerulus was rated from 0 to
4 as follows: 0, 0%; 1, o25%; 2, 25–50%; 3, 50–75%; and 4, 475%.
After the removal of parafﬁn, the slices were dehydrated in
xylene followed by in graded alcohol and immersed in distilled
water. The free kidney sections were transferred to 10 mmol/L
citrate buffer adjusted to a pH of 6.0 for various staining
methods. Sections were microwaved for 10–20 minutes to
retrieve the antigens for transforming growth factor b 1
(TGFβ1) and F4/80, and transferred to Biogenex Retrievit (pH
8.0) (InnoGenex, San Ramon, CA, USA) for PAI-1 staining or
trypsin treatment (Sigma) for 30 minutes at 371C, to detect type
IV collagen. For blocking the endogenous peroxidase activity,
3.0% H2O2 in methanol was applied to the tissues for 20
minutes, followed by incubation at room temperature for
60 minutes with 3% bovine serum albumin (BSA)/3% normal
goat serum (type IV collagen), 90 minutes with 5% normal goat
serum, and either 15 minutes with 10% powerblock (PAI-1) or
30 minutes with 20% normal sheep serum (TGFβ1). Slides were
incubated overnight at 41C with rabbit polyclonal anti-TGFβ1
antibody (1:200; Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), mouse monoclonal anti-F4/80 antibody (1:100; Serotec,
Oxford, UK), rabbit polyclonal anti-type IV collagen antibody
(1:200; Santa Cruz Biotechnology Inc.), or rabbit polyclonal
anti-PAI-1 antibody (1:50; American Diagnostica, Stanford, CT,Table 1. Biochemical parameters in experimental animals
Week ND
Body weight (g) 0 19.07
4 25.07
8 25.27
12 26.77
Daily food intake (g/d) 0 4.257
4 3.257
8 3.127
12 3.627
Daily water intake (mg/d) 0 2.757
4 4.007
8 3.877
12 4.377
Urine volume (mL/d) 0 375.07
4 184.57
8 184.07
12 102.07
Kidney/100 g BW (103) 12 12.87
Heart/100 g BW ( 103) 12 8.07
Fat/100 g BW (103) 12 17.77
Liver/100 g BW (103) 12 78.37
Systolic BP (mmHg) 12 123.27
Creatinine (mg/dL) 12 0.457
Fasting blood glucose (mmol/L) 12 1877
HbA1c (%) 12 4.857
Plasma insulin (ng/mL) 12 1.277
Plasma adiponectin (ng/mL) 12 22,518.07
HOMA-IR§ 12 0.497
n Po0.05, versus ND.
† Po0.05, versus HFD.
‡ Po0.05, versus ND.
§ The HOMA-IR was calculated using the following formula: fasting glucose
Values are expressed as mean7SEM.
BP, blood pressure; BW, body weight; GIT27, 4,5-dihydro-3-phenyl-5-isoxas
assessment index; ND, normal chow diet; SEM, standard error of the meanUSA). After overnight incubation, the slides were incubated
again with a secondary antibody for 30 minutes and detected
by incubation at room temperature with a mixture of
0.05% 3,3′-diaminobenzidine containing 0.01% H2O2 and
counterstaining with Mayer’s hematoxylin. Negative control
sections were stained under identical conditions, but with a
buffer solution instead of the primary antibody. For the evalua-
tion of immunohistochemical staining for type IV collagen,
TGFβ1, PAI-1, and F4/80, the glomerular ﬁelds were graded
semiquantitatively under a high-power ﬁeld containing 50–60
glomeruli, and the average score was calculated as described
previously [23]. A pathologist examined and scored the histo-
logical changes in a blinded manner.
Analysis of gene expression by real-time quantitative
polymerase chain reaction
We extracted total RNA from the experimental cells using
the Trizol reagent. Primers were designed for their respective
gene sequences using the Primer 3 software, and the secondary
structures of the templates were examined and excluded using
the mfold program. Quantitative gene expression was per-
formed using a LightCycler 1.5 system (Roche Diagnostics
Corporation, Indianapolis, IN, USA) using SYBR Green technol-
ogy. In 96-well real-time polymerase chain reaction (PCR)
plates, 10 μL SYBR Green master mix was added to 1 μL of
RNA (corresponding to 50 ng of total RNA) and 900nM of both
forward and reverse primers for a total reaction volume of
20 μL. Real-time reverse transcriptase PCR was performed for
10 minutes at 501C and for 5 minutes at 951C. Thirty PCR cyclesHFD HFDþGIT27
0.70 19.770.25 19.770.50
0.40 29.070.81* 26.170.73†
0.75 35.270.85* 32.071.17†,‡
0.85 41.071.58* 39.271.50†,‡
0.35 3.5070.35 3.1570.82
0.01 1.2570.35 1.7271.47
0.53 2.070.35 1.7070.34
0.17 1.6270.88 2.0070.91
0.70 4.2570.35 4.2571.09
0.01 1.6270.17 2.1870.48
0.17 2.2570.35 2.4370.34
0.17 2.5070.35 2.2670.43
197.7 315.0761.9 531.147100.2
18.5 18.4789.1 183.9750.1
45.5 417.77148.0* 447.17100.9
12.9 168.0757.3 206.4760.9
0.5 7.470.2* 8.470.00‡
0.03 7.370.4 7.370.3
2.2 58.171.8* 49.772.8‡
3.0 77.577.9 70.673.2
3.4 112.0711.1 114.176.0
0.03 0.4070.04 0.3270.03
6.5 17679.2 17974.2
0.05 4.9770.11 5.0570.07
0.73 3.5271.52 1.970.35
3,275.0 29,369.072,616.2 28,889.871,636.8
0.28 1.7770.83 0.9170.14
(mmol/L) fasting insulin (mU/L)/22.5.
ole acetic acid; HFD, high fat chow diet; HOMA-IR, homeostasis model
.
Kidney Res Clin Pract 33 (2014) 33–4436of denaturation for 10 seconds at 951C and annealing with
extension for 30 seconds at 601C were then conducted. Gene-
level ratios relative to β-actin (relative gene expression number)
were calculated by subtracting the threshold cycle number of
the target gene from that of β-actin and squaring this difference.
We evaluated the speciﬁcity of each PCR product using melting
curve analysis, followed by agarose gel electrophoresis.
Protein extraction and Western blot analysis
We extracted nuclear and cytoplasmic proteins from renal
cortical tissues and cells using a commercial nuclear extraction kit
according to the manufacturer’s instructions (Active Motif, Carls-
bad, CA, USA). Protein concentration was determined using the
bicinchoninic acid method (Pierce Pharmaceuticals, Rockford, IL,
USA). For Western blotting, 40 μg of protein was electrophoresed
on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis (SDS-PAGE) mini-gel. Proteins were transferred onto a
polyvinylidene diﬂuoride membrane and the membrane was
hybridized in blocking buffer overnight at 41C with goat polyclonalBaseline
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Figure 1. Effects of GIT27 on glucose tolerance test. After 4 weeks, plasma
in ND mice (Po0.05). GIT27 treatment improved glucose tolerance (Po0.05
4,5-dihydro-3-phenyl-5-isoxasole acetic acid; HFD, high-fat chow diet; ND,anti-TLR4 antibody (1:500, Santa Cruz Biotechnology Inc.), goat
polyclonal anti-TRAF6 antibody (1:500, Santa Cruz Biotechnology
Inc.), rabbit polyclonal anti-NOX4 antibody (1:500, Novus Biologi-
cals), rabbit polyclonal anti-NFκB (p65) antibody (1:1,000, Cell
Signaling Technology, Danvers, MA, USA), mouse monoclonal
anti-inhibitory kappa B (IκB)β antibody (1:1,000, Cell Signaling
Technology), anti-p-AMP-dependent kinase (AMPK) antibody,
anti-AMPK antibody, anti-sterol regulatory element binding
transcription protein1 (SREBP1) antibody, and mouse monoclonal
anti-β-actin antibody (1:5,000, Sigma). The membrane was sub-
sequently incubated with horseradish peroxidase-conjugated sec-
ondary antibody (diluted 1:1,000) for 60 minutes at room
temperature. We detected the speciﬁc signals using an enhanced
chemiluminescence method (Amersham, Buckinghamshire, UK).
Cell culture
We cultured podocytes to elucidate the molecular mechan-
ism of TLR4 because TLR4 expression was detected preferen-
tially in glomerular podocytes. Conditionally immortalized†
4 weeks
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glucose levels increased signiﬁcantly in HFD mice compared with those
). * Po0.05, HFD versus HFDþGIT27. † Po0.05, ND versus HFD. GIT27,
normal chow diet.
Min et al / TLR antagonist for kidney disease 37mouse podocytes were cultured as described previously [24].
Brieﬂy, frozen podocytes were ﬁrst grown under permissive
conditions at 331C in RPMI 1640 media containing 10% fetalFigure 2. Effects of GIT27 on plasma lipid proﬁles. Lipid abnormalities
improved signiﬁcantly in GIT27-treated HFD mice (Po0.05). * Po0.05,
ND versus HFD. † Po0.05, HFD versus HFD+GIT27. GIT27, 4,5-dihydro-3-
phenyl-5-isoxasole acetic acid; HDL, high-density lipoprotein; HFD, high-
fat chow diet; LDL, low-density lipoprotein; ND, normal chow diet.
Figure 3. Effects of GIT27 on tissue lipid content, lipid peroxidation, a
(A) cholesterol and (B) triglyceride were higher in the adipose tissue. (C) Lipi
higher in HFD mice and decreased signiﬁcantly in GIT27-treated HFD mice
decreased by GIT27 treatment. * Po0.05, ND versus HFD. † Po0.05, ND ve
acid; HFD, high-fat chow diet; ND, normal chow diet.bovine serum (FBS), 50 U/mL IFN-γ, and 100 μg/mL antibiotics
in collagen-coated ﬂasks. The IFN-γ was gradually reduced to
10 U/mL in successive passages. Cells were then trypsinized
and subcultured without IFN-γ (nonpermissive conditions) and
allowed to differentiate at 371C, with changing the medium on
alternate days. Differentiation of the podocytes grown for at
least 8 days at 371C was conﬁrmed by identiﬁcation of the
podocyte differentiation marker synaptopodin using Wes-
tern blotting (data not shown). The 3T3-L1 cells were
obtained from American Type Culture Collection (Manassas,
VA, USA) and were maintained in Dulbecco’s modiﬁed
Eagle’s medium containing 10% FBS and 100 μg/mL anti-
biotics at 371C under a humidiﬁed 5% CO2 atmosphere.
Differentiation of the preadipocytes into adipocytes was
induced by the addition of a hormone cocktail, as described
previously [25]. Brieﬂy, 2 days after conﬂuence, the medium
was replaced with a standard adipocyte differentiation
induction medium containing 0.5 mmol/L isobutylmethyl-
xanthine, 1 μmol/L dexamethasone, and 10 μg/mL insulin.
Identiﬁcation of oil-red O-stained lipid droplets in the
cytoplasm, quantiﬁcation of the intracytoplasmic lipids,
and the expression of peroxisome proliferator activator
receptorγ (PPARγ) (data not shown) were used to conﬁrm
the differentiation of adipocytes. For palmitate preparation,
palmitate-free acids and low-endotoxin BSA (FFA free) werend oxidative stress. Compared to the kidneys and liver, the level of
d peroxide levels in the kidneys, adipose tissue, and liver were markedly
. (D) Urinary 8-isoprostane was increased markedly in HFD mice and
rsus HFD. Cr, creatinine; GIT27, 4,5-dihydro-3-phenyl-5-isoxasole acetic
*,‡
week week
Figure 4. Effects of GIT27 on proteinuria. Urinary protein excretion was signiﬁcantly higher in HFD mice than in ND mice. (A) This was improved
signiﬁcantly after GIT27 treatment. (B) After 12 weeks of experiment, urinary albumin excretion was improved markedly in GIT27-treated HFD mice
compared with that in HFD mice. * Po0.05, ND versus HFD. † Po0.05, HFD versus HFDþGIT27. ‡ Po0.05, ND versus HFDþGIT27. Cr, creatinine;
GIT27, 4,5-dihydro-3-phenyl-5-isoxasole acetic acid; HFD, high-fat chow diet; ND, normal chow diet.
Figure 5. Anti-inﬂammatory and antiﬁbrotic effects of GIT27. (A) Levels of TNFα and IL-2 in urine were increased in HFD mice and decreased in
GIT27-treated HFD mice. In particular, the level of IL-2 was improved signiﬁcantly in GIT27-treated HDF mice compared with that in HFD mice. (B) The
gene expression of proinﬂammatory cytokines such as MCP-1, PAI-1, and TNFα in the adipose tissue tended to increase in HFD mice and decrease in
GIT27-treated HFD mice. (C and D) The gene expression of proinﬂammatory and proﬁbrotic cytokines in kidney tissue tended to increase in HFDmice and
decrease in GIT27-treated HFDmice and that of type IV collagen, PAI-1, MCP-1, IL-1b, and SREBP1 were decreased signiﬁcantly in GIT27-treated HFDmice
compared with that in HFD mice. * Po0.05, HFD versus HFDþGIT27. † P o0.05, HFD versus HFD+GIT27. ‡ Po0.05, ND versus HFD. ABCA, adenosine
triphosphate-binding cassette transporter A; AMPK, AMP-dependent kinase; Col(IV), type lV collagen alpha; Cr, creatinine; FAS, fatty acid synthase; GIT27,
4,5-dihydro-3-phenyl-5-isoxasole acetic acid; HFD, high-fat chow diet; HMG coA, 3-hydroxy-3-methylglutaryl-coenzyme A; IL, interleukine; INF-γ,
interferon gamma; MCP, monocyte chemoattractant protein; ND, normal chow diet; PAI, plasminogen activator inhibitor; PPARγ, peroxisome proliferator
activator receptor gamma; SREBP, sterol-regulatory element-binding protein; TGF, transforming growth factor; TNF, tumor necrosis factor.
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Min et al / TLR antagonist for kidney disease 39purchased from Sigma-Aldrich. A 20mM solution of palmi-
tate was dissolved in 0.01M NaOH, incubated at 701C for 30
minutes, and complexed to 10% BSA at a molar ratio of 6.6:1
in podocytes and 3:1 in adipocytes. The solution was shaken†
*
*
†
Figure 6. Renal pathology and immunohistochemistry. (A) Representative
staining for PAS, type IV collagen, PAI-1, F4/80, and TGFβ1 were increased in H
400 for PAS, type IV collagen, F4/80 staining, and TGF-β1 staining; and
glomerulosclerosis and the immunostaining scores in the kidney tissue. Data
versus HFDþGIT27. ‡ Po0.05 ND versus HFD. GIT27, 4,5-dihydro-3-phenyl-5
diet; ND, normal chow diet; PAI-1, plasminogen activator inhibitor-1; PAS, p
growth factor.overnight at 371C under N2, sonicated for 10 minutes, ﬁlter
sterilized, and stored at 20 1C prior to use [26,27]. Cells
were cultivated on 100-mm dishes and serum restricted for
24 hours. These were subsequently exposed to normal†
†
*
‡
sections show that the histological changes and immunohistochemical
FD mice and decreased in GIT27-treated HFD mice (original magniﬁcation
1000 for PAI-1 staining). (B) Bar graphs represent quantiﬁcation of
are shown as the mean7SEM. * P o0.01 ND versus HFD. † Po0.05 HFD
-isoxasole acetic acid; GSI, glomerulosclerosis index; HFD high-fat chow
eriodic acid-Schiff; SEM, standard error of the mean; TGF, transforming
Kidney Res Clin Pract 33 (2014) 33–4440glucose (NG; 5.5mM) or high glucose (HG; 30mM) with or
without palmitate (100μM) for 24 hours. To evaluate the
effects of TLR antagonism, GIT27 was added to the cells
2 hours prior to exposure at a concentration of 10 μg/mL.
After the experiment, the cell lysates and conditioned media
were centrifuged at 15,000 rpm for 10 minutes at 41C, and the
supernatants were collected. All experimental groups were
cultured in triplicate and harvested at 24 hours.
Statistical analysis
We used nonparametric analysis for the relatively small
number of samples. Results are expressed as mean7standard
error of the mean. Comparisons were made using the Wilcoxon
rank sum test and Bonferroni correction. A Kruskal–Wallis
test was used for comparison of more than two groups, followed
by a Mann–Whitney U test. A P value of o0.05 was considered
statistically signiﬁcant. The statistical analyses were performed
using SPSS for Windows, version 13.0 (SPSS Inc., Chicago, IL, USA).ND HFD HFD+GIT27
TLR4
NF-κB(p65)
IκBβ
NOX4
SP-1
Figure 7. TLR4/NFκB pathway in animal experiments. Protein synth-
esis for TLR4, NFκB, IκBβ, and NOX4 did not show a signiﬁcant change in
renal cortical tissues among ND, HFD, and GIT27-treated HFD mice.
GIT27, 4,5-dihydro-3-phenyl-5-isoxasole acetic acid; HFD, high-fat
chow diet; IκB, inhibitory kappa B; ND, normal chow diet; NFκB, nuclear
factor kappa B; NOX, nicotinamide adenine dinucleotide phosphate
oxidase; TLR, Toll-like receptor.Results
Biochemical parameters in the experimental animals
The physical and biochemical parameters for each group of
the experimental animals are shown in Table 1. As expected,
body weights of HFD mice were much higher than those of ND
mice, despite the former group taking smaller amounts of food
and water. However, interestingly, GIT27 treatment reduced
body weight in HFD mice without any changes in food and
water intake. We observed signiﬁcant changes in fat content of
each organ and in kidney weight. Fat weight increased
signiﬁcantly in HFD mice and decreased with GIT27 treatment.
However, kidney weight decreased in HFD mice and was
restored with GIT27 treatment. No changes were observed in
the weight of the heart and liver. In HFD mice, larger urinary
volumes were recorded, which were not affected by GIT27.
HFD mice did not show any signiﬁcant changes in systolic
blood pressure and serum creatinine level as compared to ND
mice. The plasma glucose and HbA1c levels were not different
among the three groups. The plasma insulin level was higher
in HFD mice than in ND mice, but this difference was not
signiﬁcant. Among the three groups, no changes were
observed in plasma adiponectin. HOMA-IR was signiﬁcantly
lower in HFD mice treated with GIT27 for 8 weeks compared
to those without GIT27 treatment.
Metabolic effects, lipid peroxidation, and oxidative stress of
GIT27 in experimental animals
To evaluate glucose tolerance, we measured blood glucose
levels after oral dextrose gavage every 4 weeks. Interestingly,
GIT27 treatment improved blood glucose levels in HFD mice
signiﬁcantly at 4, 8, and 12 weeks, although variable levels
were observed in ND mice after 12 weeks (Fig. 1A–D).
In accordance with glucose tolerance, lipid abnormalities also
improved signiﬁcantly in HFD mice by GIT27 treatment
(Fig. 2). In addition, lipid contents in the kidneys, fat, and liver
also showed a signiﬁcant decrease by GIT27 treatment (Fig. 3A
and B). We also compared the oxidative stress in each organ
among the three groups. An assessment of the LPO contents
and urinary 8-isoprostane levels of the kidneys, fat, and livershowed that the LPO contents were markedly higher in HFD
mice, which were decreased signiﬁcantly by GIT27 treatment
(Fig. 3C). The level of urinary 8-isoprostane was increased
markedly in HFD mice and decreased in GIT27-treated HDF
mice, but the differences were not signiﬁcant (Fig. 3D).
Renal effects of GIT27 in experimental animals
To examine the effect of GIT27 on renal injury, we ﬁrst
measured urinary excretion of protein and albumin. Urin-
ary protein excretion was increased markedly in HFD mice
compared with that in ND mice, as shown in Fig. 4A.
However, urinary protein excretion was improved signiﬁ-
cantly after treatment with GIT27. Fig. 4B shows the urine
albumin excretion in 24 hours. After 12 weeks, urinary
albumin excretion was also improved signiﬁcantly in
GIT27-treated HFD mice compared with HFD mice without
treatment. Next, we evaluated the anti-inﬂammatory effect
of GIT27 on obesity-induced renal injury after conﬁrming
metabolic improvement and an antiproteinuric effect. We
also compared the urinary levels of proinﬂammatory cyto-
kines (TNFα and IL-2) among the three groups based on an
analysis of the 24-hour urine samples using an ELISA kit.
The levels of TNFα and IL-2 in the urine were increased in
HFD mice and decreased in GIT27-treated HFD mice. In
particular, the IL-2 level was improved signiﬁcantly in
GIT27-treated HFD mice compared with HFD mice without
treatment (Fig. 5A). Moreover, we evaluated the gene
expression of the adipose and kidney tissues to conﬁrm
the anti-inﬂammatory and antiﬁbrotic effects of GIT27
treatment. The gene expression of proinﬂammatory cyto-
kines such as MCP-1, PAI-1, and TNFα in the adipose tissue
was increased in HFD mice and decreased by GIT27 treat-
ment (Fig. 5B). No signiﬁcant change was recorded in PPARγ
and adiponectin gene expression. AMPK gene expression
was increased signiﬁcantly in HFD mice, which decreased
by GIT27 treatment. Gene expressions of proinﬂammatory
and proﬁbrotic cytokines in the kidney tissue tended to
increase in HFD mice and decrease in those treated with
GIT27. In particular, gene expressions of type IV collagen,
PAI-1, MCP-1, and IL-1b were decreased signiﬁcantly in
GIT27-treated HFD mice compared with HDF mice without
treatment (Fig. 5B and C). With regard to lipid metabolism
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Figure 8. TLR4/NFκB pathway in cultured podocytes. (A, B) FFA induced NFκB activation and IκBβ inhibition in podocytes, which were suppressed
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by GIT27 treatment.
Fig. 6 shows the representative immunohistochemical ﬁnd-
ings for each group of experimental animals. We observed higher
extracellular matrix expansion and tubulointerstitial ﬁbrosis, and
increased expression of type IV collagen, TGFβ1, and PAI-1 in HFD
mice. Consistent with the results of the urinary albumin excre-
tion, the expression of these genes was decreased by GIT27
treatment compared to that in HFD mice without treatment. The
expression of F4/80 as a macrophage marker was increased in
HFD mice and reduced in GIT27-treated HFD mice. This resultsuggests that GIT27 restored the renal inﬂammatory changes by
suppressing macrophage accumulation in the kidneys.
TLR4 pathway and the effect of GIT27 in experimental animals
To understand the mechanism of the beneﬁcial effects of GIT27
relating to the TLR4 pathway, we investigated TLR4, NFκB, IκBβ,
and NOX4 protein synthesis in the kidneys of ND mice and HFD
mice with and without GIT27 treatment. The expression of TLR4
showed a tendency to increase in HFD mice, which decreased
with GIT27 treatment; however, these changes were not
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Figure 9. TLR4/NFκB pathway in adipocytes. In adipocytes, no changes
were observed in the protein expression of SREBP1, TLR4, NFκB, IκBβ,
NOX4, and p-AMPK. AMPK, AMP-dependent kinase; FFA, free fatty acid;
GIT27,4,5-dihydro-3-phenyl-5-isoxasole acetic acid; HG, high glucose;
IκB, inhibitory kappa B; NFκB, nuclear factor kappa B; NG, normal
glucose; NOX, nicotinamide adenine dinucleotide phosphate oxidase;
SREBP1, sterol regulatory element binding transcription protein1; TLR,
Toll-like receptor.
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no change in HFDmice with and without GIT27 treatment (Fig. 7).
TLR4 pathway in cultured podocytes and adipocytes under
FFA conditions
We conﬁrmed previously that TLR4 mRNA expression was
increased markedly under FFA and HG conditions in cultured
podocytes [18]. This effect was notable upon exposure to both
HG and FFAs. Consistent with these changes, proinﬂammatory
cytokine secretion into the culture supernatant was also
increased tremendously in FFA conditions. Moreover, HG and
FFA also increased NFκB activation. However, GIT27 interest-
ingly inhibited TLR4, TNFα, NOX4 expression, NFκB activation,
and proinﬂammatory cytokine synthesis. The protein synthesis
results of this study agreed with the ﬁndings of previous
studies. In particular, FFA induced NFκB activation and IκBβ
inhibition in podocytes (Fig. 8). Additionally, GIT27 suppressed
NFκB activation and reactivated IκBβ inhibition signiﬁcantly.
The protein expression of TLR4, TRAF6, NOX4, p-AMPK, and
SREBP1 tended to increase under FFA conditions, but the trend
was reversed by GIT27 treatment; however these changes
were not signiﬁcant in Western blot analysis. In addition, with
regard to adipocytes, no signiﬁcant changes were observed in
the protein expression of SREBP1, TLR4, NFκB, IκBβ, NOX4, and
p-AMPK (Fig. 9).Discussion
In our study, we demonstrated that the TLR antagonist
GIT27 improved obesity-related renal injury through the
suppression of inﬂammatory changes in both the kidneys
and the adipose tissue. GIT27, a novel immunomodulatory
compound, modulates macrophage function and inhibits NFκB
and proinﬂammatory cytokines through the TLR4 and TLR2/3
signaling pathways [19,20]. Our study showed that GIT27
treatment in animals with HFD-induced obesity improved
their metabolic disorders such as glucose intolerance and lipidabnormalities. Moreover, GIT27 treatment also decreased the
urinary excretion of albumin and protein in obesity-related
kidney disease, urinary oxidative stress markers, and inﬂam-
matory cytokine levels, and inhibited the expression of oxida-
tive stress and proinﬂammatory cytokines in the kidneys and
adipose tissue. In addition, GIT27 treatment improved extra-
cellular matrix expansion and tubulointerstitial ﬁbrosis in
obesity-related kidney disease.
Recent works have proved that adipose tissue is a highly
metabolic organ with pluripotent functions far beyond the
mere storage of energy. Adipose tissue is now considered an
endocrine organ that secretes a large number of bioactive
cytokines, which have essential roles in energy homeostasis,
glucose and lipid metabolism, insulin resistance, inﬂamma-
tion, and atherosclerosis [28,29]. Obesity and its related
metabolic diseases are believed to involve chronic low-grade
inﬂammation characterized by the activation of proinﬂamma-
tory cytokines and inﬁltration of macrophages into adipose
tissue, leading to increased oxidative stress and insulin resis-
tance. Molecular mechanisms underlying macrophage recruit-
ment into adipose tissue are unclear. However, recent reports
have revealed that stimuli such as LPS and FFAs activate the
intracellular transcriptional NFκB pathway via the TNF recep-
tor 1, IL-6 receptor, and TLR. Tremendous progress has been
made to discover the role of the TLR family of proteins as a key
component of the innate immunity system and in various
inﬂammatory responses [30]. TLR4 is the most attractive
candidate for investigating the connection between innate
immunity and metabolic disorders [31,32]. The NFκB signaling
pathway in adipose tissue macrophages is considered to be a
link between TLR4, obesity, and insulin resistance.
In our study, we conﬁrmed that the number of F4/80-
expressing cells increased in the kidney tissue of obese mice
and decreased with GIT27 treatment. This result is interesting,
despite a previous study investigating the role of macrophages in
various kidney disease models [33]. Low-grade inﬂammation due
to the inﬁltration of macrophages into the kidneys and adipose
tissue has been shown to be induced by obesity and modulated
by the TLR antagonist. GIT27 decreased urinary albumin excre-
tion, oxidative stress, and activation of proinﬂammatory mole-
cules in both the kidneys and adipose tissue of HFD mice.
However, although these immunomodulatory effects of TLR
antagonist on macrophages have already been known, its effect
on the kidneys has rarely been reported. We hypothesized that
GIT27 can show its direct effects on both kidney cells and
adipocytes through inhibition of the TLR signaling pathway. As
expected, in vivo data showed that GIT27 improved obesity-
induced inﬂammatory changes in both the kidneys and adipose
tissue. These results suggest that the TLR pathway may play a
central role in the crosstalk between the kidneys and adipose
tissue in obesity. However, we could not observe a notable
change in TLR4 expression within the kidneys by GIT27 treat-
ment. The expression of the TLR signaling pathway tended to
increase in the kidneys of HFD mice and decrease in those
treated with GIT27, but this difference was not signiﬁcant. This
may be explained by the fact that GIT27 is not a selective
antagonist for TLR4 and has different cell- or organ-speciﬁc
effects depending on speciﬁc diseases. Another explanation could
be that it may exert a beneﬁcial effect on the kidneys through an
indirect mechanism of improvement of metabolic parameters
such as glucose tolerance and lipid proﬁles. To investigate the
direct effect of glucose and lipid stimulation on the kidney cells
and adipocytes, we cultured podocytes and adipocytes and then
Min et al / TLR antagonist for kidney disease 43treated themwith HG and FFA. We conﬁrmed TLR4 expression in
cultured podocytes previously, and TLR4 mRNA expression was
increased markedly under HG conditions in those cells [18].
Interestingly, in this study, HG and FFA stimulated a TLR signaling
pathway in cultured podocytes. In particular, FFA increased the
synthesis of NFκB and IκBβ, which were inhibited signiﬁcantly by
GIT27. However, these changes were not observed in mesangial
cells (data not shown). These results suggest that the TLR
antagonist can have its direct effect on the kidneys through
podocyte injury. By contrast, the TLR antagonist did not affect
adipocytes. The protein expression of SREBP1, TLR4, NFκB, IκBβ,
NOX4, and p-AMPK in adipocytes was not changed signiﬁcantly
by FFA and GIT27. These results suggest that macrophage
recruitment into the adipose tissue may have a more crucial role
in obesity-induced immunomodulatory inﬂammatory mechan-
ism than changes of adipocytes.
Our study presents the limitation that we could not identify
a signiﬁcant change of the TLR pathway in the kidneys of HFD
mice. However, this result is interesting because an inhibition of
TLR expression by the TLR antagonist was more remarkable in
the kidneys of a diabetic animal model than in those of an obese
animal model. We demonstrated previously that urinary
nephrin excretion was more enhanced in diabetic mice than
in nondiabetic mice, and GIT27 decreased nephrin excretion
signiﬁcantly in a podocyte injury model of diabetic nephropathy
[18]. Lin et al [34] recently reported that the TLR4 antagonist
CRX-526 attenuated renal injury through the TGFβ and NFκB
pathways in advanced diabetic nephropathy. Both the studies
proved that the TLR antagonist inhibited the expression of TLR
pathway signiﬁcantly in the kidneys of diabetic nephropathy
animal. We also observed a dramatic change in the expression
of NFκB and IκBβ in podocytes by FFA and GIT27. All these
results suggest that the TLR antagonist improves obesity-
induced kidney injury. In particular, their mechanism may at
least partially be associated with the TLR signaling pathway in
podocyte injury. This TLR signaling pathway may be related to
the nephrin expression in podocyte injury [18]. Further studies
may develop a TLR antagonist that is selective for TLR4 and
speciﬁc to different organ and diseases, in order to eventually
uncover the exact mechanisms involved.
In conclusion, the TLR antagonist GIT27 improved metabolic
disorder and exerted renoprotective effects on obesity-related
kidney disease through its anti-inﬂammatory properties. These
effects were associated with the TLR pathway of podocyte
injury. Further study to elucidate the renoprotective mechanism
of a TLR antagonist is under investigation. In the near future,
GIT27 may be used in the treatment of multiple renal diseases
associated with innate immunity.Conﬂicts of interest
The authors declare no conﬂicts of interest.Acknowledgments
This study was supported by a grant from Korea University.
References
[1] Cignarelli M, Lamacchia O: Obesity and kidney disease. Nutr
Metab Cardiovasc Dis 17:757–762, 2007[2] Kang YS, Cha JJ, Hyun YY, Cha DR, Novel C–C: chemokine receptor
2 antagonists in metabolic disease: a review of recent develop-
ments. Expert Opin Investig Drugs 20:745–756, 2011
[3] Wickman C, Kramer H: Obesity and kidney disease: potential
mechanisms. Semin Nephrol 33:14–22, 2013
[4] Amann K, Benz K: Structural renal changes in obesity and
diabetes. Semin Nephrol 33:23–33, 2013
[5] Kang SC, Kim BR, Lee SY, Park TS: Sphingolipid metabolism and
obesity-induced inﬂammation. Front Endocrinol 4:1–11, 2013
[6] Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL,
Ferrante Jr AW: Obesity is associated with macrophage accumula-
tion in adipose tissue. J Clin Invest 112:1796–1808, 2003
[7] Kwon H, Pessin JE: Adipokines mediate inﬂammation and insulin
resistance. Front Endocrinol 4:1–13, 2013
[8] Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A,
Dandona P: Elevation of free fatty acids induces inﬂammation and
impairs vascular reactivity in healthy subjects. Diabetes 52:
2882–2887, 2003
[9] Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links
innate immunity and fatty acid-induced insulin resistance. J Clin
Invest 116:3015–3025, 2006
[10] Lee JY, Sohn KH, Rhee SH, Hwang D: Saturated fatty acids, but not
unsaturated fatty acids, induce the expression of cyclooxygenase-2
mediated through Toll-like receptor 4. J Biol Chem 276:16683–16689,
2001
[11] Takeda K, Akira S: TLR signaling pathways. Semin Immunol 16:3–9,
2004
[12] Zuany-Amorim C, Hastewell J, Walker C: Toll-like receptors as
potential therapeutic targets for multiple diseases. Nat Rev Drug
Discov 1:797–807, 2002
[13] Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, Alexander
SI, Sharland AF, Chadban SJ: TLR4 activation mediates kidney
ischemia/reperfusion injury. J Clin Invest 117:2847–2859, 2007
[14] Cunningham PN, Wang Y, Guo R, He G, Quigg RJ: Role of Toll-like
receptor 4 in endotoxin-induced acute renal failure. J Immunol
172:2629–2635, 2004
[15] Goldstein DR, Tesar BM, Akira S, Lakkis FG: Critical role of the Toll-
like receptor signal adaptor protein MyD88 in acute allograft
rejection. J Clin Invest 111:1571–1578, 2003
[16] Liu B, Yang Y, Dai J, Medzhitov R, Freudenberg MA, Zhang PL, Li Z:
TLR4 up-regulation at protein or gene level is pathogenic
for lupus-like autoimmune disease. J Immunol 177:6880–6888,
2006
[17] Brown HJ, Lock HR, Wolfs TG, Buurman WA, Sacks SH, Robson
MG: Toll-like receptor 4 ligation on intrinsic renal cells contri-
butes to the induction of antibody-mediated glomerulonephritis
via CXCL1 and CXCL2. J Am Soc Nephrol 18:1732–1739, 2007
[18] Cha JJ, Hyun YY, Lee MH, Kim JE, Nam DH, Song HK, Kang YS, Lee
JE, Kim HW, Han JY, Cha DR: Renal protective effects of Toll-like
receptor 4 signaling blockade in type 2 diabetic mice. Endocrinol-
ogy 154:2144–2155, 2013
[19] Stosic-Grujicic S, Cvetkovic I, Mangano K, Fresta M, Maksimovic-
Ivanic D, Harhaji L, Popadic D, Momcilovic M, Miljkovic D, Kim J,
Al-Abed Y, Nicoletti F: A potent immunomodulatory compound,
(S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents
spontaneous and accelerated forms of autoimmune diabetes in
nod mice and inhibits the immunoinﬂammatory diabetes induced
by multiple low doses of streptozotocin in CBA/H mice. J Pharma-
col Exp Ther 320:1038–1049, 2007
[20] Stojanovic I, Cuzzocrea S, Mangano K, Mazzon E, Miljkovic D,
Wang M, Donia M, Al Abed Y, Kim J, Nicoletti F, Stosic-Grujicic S,
Claesson M: In vitro, ex vivo and in vivo immunopharmacological
activities of the isoxazoline compound VGX-1027: Modulation of
cytokine synthesis and prevention of both organ-speciﬁc and
systemic autoimmune diseases in murine models. Clin Immunol
123:311–323, 2007
[21] Mangano K, Sardesai N, D'Alcamo M, Libra M, Malaguarnera L,
Donia M, Bendtzen K, Meroni P, Nicoletti F: In vitro inhibition of
enterobacteria-reactive CD4þCD25-T cells and suppression of
Kidney Res Clin Pract 33 (2014) 33–4444immunoinﬂammatory colitis in mice by the novel immunomo-
dulatory agent VGX-1027. Eur J Pharmacol 586:313–321, 2008
[22] Bligh EG, Dyer WJ: A rapid method of total lipid extraction and
puriﬁcation. Can J Biochem Physiol 37:911–917, 1959
[23] Lee MH, Song HK, Ko GJ, Kang YS, Han SY, Han KH, Kim HK, Han
JY, Cha DR: Angiotensin receptor blockers improve insulin resis-
tance in type 2 diabetic rats by modulating adipose tissue. Kidney
Int 74:890–900, 2008
[24] Han SY, Kang YS, Jee YH, Han KH, Cha DR, Kang SW, Han DS: High
glucose and angiotensin ll increase beta1 integrin and integrin-
linked kinase synthesis in cultured mouse podocytes. Cell Tissue
Res 323:321–332, 2006
[25] Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R:
Isoproterenol inhibits resistin gene expression through a G(S)-
protein-coupled pathway in 3T3-L1 adipocytes. FEBS Lett 500:
60–63, 2001
[26] Dasu MR, Jialal I: Free fatty acids in the presence of high glucose
amplify monocyte inﬂammation via Toll-like receptors. Am
J Physiol Endocrinol Metab 300:E145–E154, 2011
[27] Sieber J, Lindenmeyer MT, Kampe K, Campbell KN, Cohen CD,
Hopfer H, Mundel P, Jehle AW: Regulation of podocyte survival
and endoplasmic reticulum stress by fatty acids. Am J Physiol Renal
Physiol 299:F821–F829, 2010[28] Guzik TJ, Mangalat D, Korbut R: Adipocytokines—novel link
between inﬂammation and vascular function? J Physiol Pharmacol
57:505–528, 2006
[29] Lago F, Dieguez C, Gomez-Reino J, Gualillo O: Adipokines as
emerging mediators of immune response and inﬂammation. Nat
Clin Pract 3:716–724, 2007
[30] Nagai Y, Watanabe Y, Takatsu K: The TLR family protein RP105/
MD-1 complex: a new player in obesity and adipose tissue
inﬂammation. Adipocyte 2:61–66, 2013
[31] Majdalawieh A, Ro HS: Regulation of IκBα function and NF-κB
signaling: AEBP1 is a novel proinﬂammatory mediator in macro-
phages. Mediators Inﬂamm 823821:1–27, 2010
[32] Schafﬂer A, Scholmerich J: Innate immunity and adipose tissue
biology. Trends Immunol 31:228–235, 2010
[33] Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser
WG, Seidel K: Cellular events in the evolution of experimental
diabetic nephropathy. Kidney Int 47:935–944, 1995
[34] Lin M, Yiu WH, Li RX, Wu HJ, Wong DW, Chan LY, Leung JC, Lai KN,
Tang SC: The TLR4 antagonist CRX-526 protects against advanced
diabetic nephropathy. Kidney Int 83:887–900, 2013
